221 related articles for article (PubMed ID: 34741719)
1. Thromboembolism in Patients with Metastatic Renal Cell Carcinoma Treated with Immunotherapy.
Sheng IY; Gupta S; Reddy CA; Angelini D; Funchain P; Sussman TA; Sleiman J; Ornstein MC; McCrae K; Khorana AA
Target Oncol; 2021 Nov; 16(6):813-821. PubMed ID: 34741719
[TBL] [Abstract][Full Text] [Related]
2. Risk of Thromboembolism in Patients Receiving Immunotherapy-Based Combinations as Front-Line Therapy for Metastatic Renal Cell Carcinoma.
Schuster J; Sheng IY; Reddy CA; Khorana AA; Nizam A; Gupta S; Gilligan T; Wee CE; Sussman TA; Bonham A; Maroli K; Martin A; Ornstein MC
Clin Genitourin Cancer; 2024 Apr; 22(2):92-97. PubMed ID: 37932205
[TBL] [Abstract][Full Text] [Related]
3. Real-world Assessment of Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma with or Without Sarcomatoid Features Treated with First-line Systemic Therapies.
Sawaya GB; Dragomir A; Wood LA; Kollmannsberger C; Basappa NS; Kapoor A; Soulières D; Finelli A; Heng DYC; Castonguay V; Canil C; Winquist E; Graham J; Bjarnason GA; Bhindi B; Lalani AK; Pouliot F; Breau RH; Saleh R; Tanguay S
Eur Urol Oncol; 2024 Jun; 7(3):570-580. PubMed ID: 38097481
[TBL] [Abstract][Full Text] [Related]
4. Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?
Santoni M; Buti S; Myint ZW; Maruzzo M; Iacovelli R; Pichler M; Kopecky J; Kucharz J; Rizzo M; Galli L; Büttner T; De Giorgi U; Kanesvaran R; Fiala O; Grande E; Zucali PA; Kopp RM; Fornarini G; Bourlon MT; Scagliarini S; Molina-Cerrillo J; Aurilio G; Matrana MR; Pichler R; Cattrini C; Büchler T; Massari F; Seront E; Calabrò F; Pinto A; Berardi R; Zgura A; Mammone G; Ansari J; Atzori F; Chiari R; Bamias A; Caffo O; Procopio G; Sunela K; Bassanelli M; Ortega C; Grillone F; Landmesser J; Milella M; Messina C; Küronya Z; Mosca A; Bhuva D; Santini D; Vau N; Morelli F; Incorvaia L; Rebuzzi SE; Roviello G; Soares A; Bisonni R; Bimbatti D; Zabalza IO; Rizzo A; Mollica V; Sorgentoni G; Monteiro FSM; Battelli N; Bracarda S; Porta C
Eur Urol Oncol; 2024 Feb; 7(1):102-111. PubMed ID: 37481365
[TBL] [Abstract][Full Text] [Related]
5. Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma.
Ernst MS; Navani V; Wells JC; Donskov F; Basappa N; Labaki C; Pal SK; Meza L; Wood LA; Ernst DS; Szabados B; McKay RR; Parnis F; Suarez C; Yuasa T; Lalani AK; Alva A; Bjarnason GA; Choueiri TK; Heng DYC
Eur Urol; 2023 Jul; 84(1):109-116. PubMed ID: 36707357
[TBL] [Abstract][Full Text] [Related]
6. Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Yip SM; Wells C; Moreira R; Wong A; Srinivas S; Beuselinck B; Porta C; Sim HW; Ernst DS; Rini BI; Yuasa T; Basappa NS; Kanesvaran R; Wood LA; Canil C; Kapoor A; Fu SYF; Choueiri TK; Heng DYC
Cancer; 2018 Sep; 124(18):3677-3683. PubMed ID: 30307610
[TBL] [Abstract][Full Text] [Related]
7. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
[TBL] [Abstract][Full Text] [Related]
8. Real-World Assessment of Clinical Outcomes Among First-Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk Group.
Savard MF; Wells JC; Graham J; Dudani S; Steinharter JA; McGregor BA; Donskov F; Bjarnason GA; Vaishampayan UN; Hansen AR; Iafolla MAJ; Zanotti G; Huynh L; Chang R; Duh MS; Heng DYC
Oncologist; 2020 May; 25(5):422-430. PubMed ID: 31971318
[TBL] [Abstract][Full Text] [Related]
9. A U.S. Food and Drug Administration-pooled Analysis of Frontline Combination Treatment Survival Benefits by Risk Groups in Metastatic Renal Cell Carcinoma.
Lee D; Gittleman H; Weinstock C; Suzman D; Bloomquist E; Agrawal S; Brave M; Brewer J; Fallah J; Singh H; Tang S; Ibrahim A; Pazdur R; Beaver JA; Amiri-Kordestani L
Eur Urol; 2023 Oct; 84(4):373-378. PubMed ID: 37271635
[TBL] [Abstract][Full Text] [Related]
10. Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model.
de Velasco G; Culhane AC; Fay AP; Hakimi AA; Voss MH; Tannir NM; Tamboli P; Appleman LJ; Bellmunt J; Kimryn Rathmell W; Albiges L; Hsieh JJ; Heng DY; Signoretti S; Choueiri TK
Oncologist; 2017 Mar; 22(3):286-292. PubMed ID: 28220024
[TBL] [Abstract][Full Text] [Related]
11. Real-World Treatment Patterns and Clinical Outcomes Among Patients With Advanced Renal Cell Carcinoma.
Esterberg E; Iyer S; Nagar SP; Davis KL; Tannir NM
Clin Genitourin Cancer; 2024 Apr; 22(2):115-125.e3. PubMed ID: 37914609
[TBL] [Abstract][Full Text] [Related]
12. Combination therapies in patients with favorable risk metastatic renal cell Carcinoma: A Systematic Review and Meta-Analysis.
Bolek H; Yekedüz E; Ürün Y
Cancer Treat Rev; 2024 Jan; 122():102667. PubMed ID: 38101099
[TBL] [Abstract][Full Text] [Related]
13. Impact of modified Glasgow prognostic score on predicting prognosis and modification of risk model for patients with metastatic renal cell carcinoma treated with first line tyrosine kinase inhibitor.
Yukihiro K; Teishima J; Goto K; Aoki G; Sekino Y; Hayashi T; Hasegawa Y; Mita K; Kato M; Kajiwara M; Shigeta M; Maruyama S; Kadonishi Y; Fujiwara S; Hinata N
Urol Oncol; 2022 Oct; 40(10):455.e11-455.e18. PubMed ID: 35851184
[TBL] [Abstract][Full Text] [Related]
14. Real World Analysis of Peritoneal Metastasis From Renal Cell Carcinoma. Meet-Uro27.
Stellato M; Buti S; Maruzzo M; Bassanelli M; Bersanelli M; Napoli MD; Dionese M; Fanelli M; Filippi R; Fotia G; Galli L; Grillone F; Maffezzoli M; Maiorano BA; Nasso C; Rebuzzi SE; Lalli L; Roviello G; Sorarù M; Vincenzi B; Procopio G; Verzoni E
Clin Genitourin Cancer; 2024 Jun; 22(3):102078. PubMed ID: 38631104
[TBL] [Abstract][Full Text] [Related]
15. Thromboembolism in Patients with Metastatic Urothelial Cancer Treated with Immune Checkpoint Inhibitors.
Sheng IY; Gupta S; Reddy CA; Angelini D; Funchain P; Sussman TA; Sleiman J; Ornstein MC; McCrae K; Khorana AA
Target Oncol; 2022 Sep; 17(5):563-569. PubMed ID: 35986816
[TBL] [Abstract][Full Text] [Related]
16. Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell Carcinoma.
Navani V; Ernst M; Wells JC; Yuasa T; Takemura K; Donskov F; Basappa NS; Schmidt A; Pal SK; Meza L; Wood LA; Ernst DS; Szabados B; Powles T; McKay RR; Weickhardt A; Suarez C; Kapoor A; Lee JL; Choueiri TK; Heng DYC
JAMA Netw Open; 2022 Jun; 5(6):e2216379. PubMed ID: 35687336
[TBL] [Abstract][Full Text] [Related]
17. Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group.
Rini BI; Hutson TE; Figlin RA; Lechuga MJ; Valota O; Serfass L; Rosbrook B; Motzer RJ
Clin Genitourin Cancer; 2018 Aug; 16(4):298-304. PubMed ID: 29853320
[TBL] [Abstract][Full Text] [Related]
18. Comparison of First-Line Anti-PD-1-Based Combination Therapies in Metastatic Renal-Cell Carcinoma: Real-World Experiences from a Retrospective, Multi-Institutional Cohort.
Hoeh B; Schmucker P; Klümper N; Hahn O; Zeuschner P; Banek S; Karakiewicz PI; Ellinger J; Heinzelbecker J; Hölzel M; Strauß A; Zengerling F; Mattigk A; Kalogirou C
Urol Int; 2022; 106(11):1150-1157. PubMed ID: 35158357
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category.
Davis ID; Xie W; Pezaro C; Donskov F; Wells JC; Agarwal N; Srinivas S; Yuasa T; Beuselinck B; Wood LA; Ernst DS; Kanesvaran R; Knox JJ; Pantuck A; Saleem S; Alva A; Rini BI; Lee JL; Choueiri TK; Heng DYC
Eur Urol; 2017 Jun; 71(6):970-978. PubMed ID: 27771126
[TBL] [Abstract][Full Text] [Related]
20. Comparative real-world survival outcomes of metastatic papillary and clear cell renal cell carcinoma treated with immunotherapy, targeted therapy, and combination therapy.
Riveros C; Ranganathan S; Xu J; Chang C; Kaushik D; Morgan M; Miles BJ; Muhammad T; Anis M; Aghazadeh M; Zhang J; Efstathiou E; Klaassen Z; Brooks MA; Rini B; Wallis CJD; Satkunasivam R
Urol Oncol; 2023 Mar; 41(3):150.e1-150.e9. PubMed ID: 36610815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]